Adalimumab antibody | AbD18664_hIgG1
A microtiter plate was coated overnight with adalimumab at a concentration of 1 μg/ml. After washing and blocking with PBST + 5% BSA, PBST with 10% human serum was added, spiked with increasing concentrations of Human Anti-Adalimumab Antibody clone AbD18654_hIgG1 (HCA202) (black), clone AbD18655_hIgG1 (HCA204) (red) or clone AbD18664_hIgG1 (HCA205) (blue). Detection was performed using HRP conjugated adalimumab at a concentration of 2 μg/ml in HISPEC Assay Diluent (BUF049A) followed by QuantaBlu Fluorogenic Peroxidase substrate. Data are shown as the mean of three measurements.
A microtiter plate was coated overnight with Recombinant Human TNFα (PHP051) at a concentration of 1 μg/ml. After washing and blocking with PBST+ 5% BSA, a pre-incubated mixture of adalimumab (0.3 μg/ml), spiked with increasing concentrations of Human Anti-Adalimumab Antibody, clone AbD18664_hIgG1 (HCA205) was added. Free adalimumab still capable of binding to the Human TNFα coated plate, was detected using a HRP conjugated Human Anti-Adalimumab (Drug/Target Complex) Antibody (HCA207) followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements. HRP conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit (LNK002P).
Human anti Adalimumab
Anti-adalimumab antibody is a recombinant, neutralizing anti-idiotypic antibody in fully human immunoglobulin format; it is suitable as a reference standard in an immune response assay to measure anti-drug antibody levels for adalimumab or biosimilars.
- Product Type
- Monoclonal Antibody
- Clone
- AbD18664_hIgG1
- Isotype
- IgG1
| Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|
| HCA205 | E | 0.1 mg |
|
Human anti Adalimumab, clone AbD18664_hIgG1, is an anti-idiotypic antibody that specifically recognizes the adalimumab monoclonal antibody and inhibits the binding of adalimumab to its target, TNFα. Clone AbD18664_hIgG1 can be used to measure the levels of adalimumab and biosimilar products using bioanalytical assays.
Adalimumab (branded as Humira®) is a fully human monoclonal antibody (IgG1/kappa) approved for the treatment of ankylosing spondylitis, Crohn’s disease, psoriasis and several forms of arthritis. The antibody is specific for TNFα, and acts by blocking the activation of TNF receptors by TNFα. This inactivation down-regulates the inflammatory reactions associated with autoimmune diseases.
View a summary of all anti-adalimumab antibodies.
Adalimumab (branded as Humira®) is a fully human monoclonal antibody (IgG1/kappa) approved for the treatment of ankylosing spondylitis, Crohn’s disease, psoriasis and several forms of arthritis. The antibody is specific for TNFα, and acts by blocking the activation of TNF receptors by TNFα. This inactivation down-regulates the inflammatory reactions associated with autoimmune diseases.
View a summary of all anti-adalimumab antibodies.
Product Details
- Product Form
- Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline.
- Preservative Stabilisers
- 0.01% Thiomersal
- Immunogen
- Adalimumab
- Affinity
- The monovalent intrinsic affinity of this antibody was measured as KD=10.5 nM by real time, label-free molecular interaction analysis on immobilized adalimumab.
- Approx. Protein Concentrations
- Antibody concentration 0.5 mg/ml.
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 12 months from date of despatch.
More Information
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.Humira® is a registered trademark of Abbott Laboratories.
- Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
- Regulatory
- For research purposes only
Applications of Adalimumab antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- ELISA
- This product may be used in an indirect ELISA or as a reference standard in immune response assays.
Protocol: ADA bridging ELISA
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Useful Reagents Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | E IY | 50 ml | ||
| Human anti Adalimumab | HCA202 | E | 0.1 mg |
|
|
| Human anti Adalimumab | HCA203 | E | 0.1 mg |
|
|
| Human anti Adalimumab | HCA204 | E | 0.1 mg |
|
|
| Human anti Adalimumab:HRP | HCA204P | E | 0.1 mg |
|
|
| Human anti Adalimumab (Drug/Target Complex) | HCA207 | E | 0.1 mg |
|
|
| LYNX Rapid HRP Antibody Conjugation Kit | LNK002P | CJ | 3 Conjugations For 400µg Antibody | ||
| Mouse anti Human IgG (Fc) CH2 Domain:HRP | MCA647P | C* E | 0.2 mg |
|
|
| Recombinant Human TNF Alpha | PHP051 | E FN WB | 50 µg |
|
